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Abstract
Background:  Nasopharyngeal carcinoma is endemic in Southern China, displays a strong
relationship with genetic susceptibility and associates with Epstein-Barr virus infection. Toll-like
receptor 3 (TLR3) plays an important role in the antivirus response. Therefore, we examined the
association between TLR3 gene polymorphisms and NPC susceptibility.
Methods: We performed a case-control study of 434 NPC cases and 512 healthy controls
matched on age, sex and residence. Both cases and controls are of Cantonese origin from Southern
China. Genetic variants in TLR3 were determined by polymerase chain reaction (PCR)-based DNA
direct sequencing and four SNPs were genotyped in all samples.
Results: Our results showed that allele C for SNP 829A/C increased NPC risk significantly ((p =
0.0068, OR = 1.49, 95%CI:1.10–2.00). When adjusted for age, gender and VCA-IgA antibody titers,
the NPC risk was reduced significantly among individuals who carried the haplotype "ATCT"
compared to those who carried the most common haplotype "ACCT" (p = 0.0054, OR = 0.028;
95% CI (0.002–0.341).
Conclusion: The TLR3 polymorphisms may be relevant to NPC susceptibility in the Cantonese
population, although the reduction in NPC risk is modest and the biological mechanism of the
observed association merits further investigation.
Background
Nasopharyngeal carcinoma (NPC) occurs sporadically in
the West (with the age – standardized incidence rat (ASR)
< 1/100,000), but is a leading form of tumor in Southern
China (ASR = 30–50/100,000) and Southeast Asia (ASR =
9–12/100,000) [1,2]. The geographical pattern of inci-
dence suggests a unique interaction of environmental and
genetic factors. Although the etiology of NPC remains to
be elucidated, genetic susceptibility [3-6], Epstein-Barr
virus (EBV) infection association [7-11], environmental
risk factors [12,13] and certain dietary factors [14,15] may
all contribute to the development of NPC. EBV, a ubiqui-
tous virus that infects more than 90% of the world's pop-
ulation by adulthood, is an important risk factor for the
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development of NPC; however, NPC occurs in only a
small percentage of the EBV-infected population [16]. The
absence of NPC in most healthy EBV carriers is reportedly
due to the effective T cell-mediated immune control of the
virus [17]. It is known that HLA class I-restricted cytotoxic
T-lymphocytes (CTLs) play an important role in control-
ling EBV infections [2]. When the cells are infected with
EBV, they express an array of EBV-associated antigens and
these viral antigens which are targeted by EBV-specific
CTLs. The responses of CTLs to EBV infection trigger a
variety of inflammatory reactions that can kill the infected
cells, while the lack of CTLs allows EBV-infected cells to
survive and proliferate [18]. It has been shown that some
EBV strains are able to escape immune surveillance in a
certain group of the population [19]. Studies in NPC cell
lines indicate that the tumor is capable of processing
endogenously expressed EBV antigens for recognition by
HLA class I-restricted CTLs, resulting in lysis of the malig-
nant cells [20].
Toll-like receptors (TLRs) have emerged as a key compo-
nent of the innate immune system that recognizes a wide
variety of pathogen-associated molecular patterns
(PAMPs) from bacteria, viruses and fungi, as well as some
host molecules [21-24]. It has been suggested that TLRs
play a central role in resisting these infections by initiating
most of the immune responses that occur during infection
[25]. Evidence has shown that TLRs control multiple den-
dritic cells capable of sensitizing naïve T cells, functions
and activates signals that are critically involved in the ini-
tiation of adaptive immune responses [26]. Due to their
ability to modulate adaptive immunity, TLRs may serve as
one of the promising strategic therapeutic targets for dis-
eases related to inappropriate adaptive immune
responses, such as sepsis, autoimmune disorders, cancer
and allergies [27].
Recently a number of viruses, including a poxvirus, her-
pesvirus, retrovirus and two paramyxoviruses, have been
shown to activate immune cells via TLRs [28-32]. TLR3 is
a receptor for double-stranded RNA (dsRNA), through
which it transmits signals to activate NF-êB and the inter-
feron -β (IFN-β) promoter and plays an important role in
antiviral responses [33-35]. Although the function of type
I interferons are most closely associated with their antivi-
ral activities, these cytokines also have diverse effector
functions in the development of adaptive immunity. Type
I interferons promote the proliferation of memory T cells
and prevent T cell apoptosis [36].
Emergent data suggest that the ability of certain individu-
als to respond properly to TLR ligands may be impaired by
single nucleotide polymorphisms (SNPs) located in the
TLR  genes, resulting in an enhanced susceptibility to
infectious or inflammatory disease [37-41]. However,
whether the genetic variants in TLR3 can alter susceptibil-
ity to NPC by affecting the anti-EBV immune responses is
unknown. We conducted a case-control study to examine
the association between genetic polymorphisms in TLR3
and risk of NPC. First, we screened the genomic regions of
TLR3 from 24 patients for potential SNPs. Then we geno-
typed four SNPs in 434 NPC patients and 512 control sub-
jects matched on age, sex and residence, both are of
Cantonese origin living in Southern China. Finally, we
evaluated the association between those 4 SNPs and the
risk of NPC occurrence.
Methods
Study population
All subjects were unrelated Cantonese speakers who live
in Guangdong Province, Southern China. Patients were
recruited from December 2003 to October 2004 with
pathologically confirmed diagnosis of NPC at the Cancer
Center, Sun Yat-sen University, Guangzhou, China. The
average age at NPC diagnosis for all 434 patients who par-
ticipated in this study was less than 50 years.
The population-based controls were cancer-free individu-
als and unrelated to the patients. These individuals were
selected randomly following a physical examination from
a community cancer-screening program for early detec-
tion of cancer conducted during the same period as the
cases were collected. The selection criteria for control sub-
jects included no individual history of cancer and
matched to NPC cases on sex, age (± 5 years), residentiary
region and date of blood sample collection. At recruit-
ment, informed consent was obtained from each subject,
who was then interviewed to collect detailed information
on demographic characteristics. Antibody titers of anti-
EBV VCA were also measured on all subjects. This study
was approved by the Human Ethics Approval Committee,
Cancer Center, Sun Yat-sen University.
Variation screening
The genomic sequence of TLR3 was obtained from the
published database of National Center for Biotechnology
Information (NCBI) database. The annotations in the
database for all known exons, intron-exons boundaries,
untranslated regions, and the 5'-flank region (promoter
region) of TLR3  were used. 12 pairs of primers were
designed for the target region using the web-based soft-
ware Primer 3.0[42]. Each expected fragment size was
between 500 and 700 bp. We amplified DNA samples
from 24 hospital-based confirmed sporadic NPC patients
at Sun Yat-sen University Cancer Center. We then
sequenced the PCR products using ABI PRISM Dye Termi-
nator Sequencing Kits and loading the samples onto an
ABI®377 Automatic Sequencer (Applied Biosystems, Fos-
ter City, CA). SNP candidates, identified using the Poly-
phred/Phredphrap/Consed software package were thenBMC Cancer 2007, 7:194 http://www.biomedcentral.com/1471-2407/7/194
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confirmed by two independent observers. The SNPs posi-
tions and individual genotypes were further confirmed by
re-amplification and reverse sequencing. SNPs, with
minor allele frequencies above 5%, were entered later for
genotype analysis for the case-control study.
Genotype analysis
Genotype variations were determined by the PCR-based
DNA direct sequencing. Genomic DNA was extracted
from the peripheral blood samples of all patient cases and
control subjects using the DNA zol kit with the protocol
from the manufacturer (GibcoBRI, Life Technologies).
This genomic DNA sample was amplified by PCR using a
GeneAmp9700 PCR System (Applied Biosystems, Foster
City CA). The PCR system used a 20-µl reaction mixture
containing 20 ng DNA, 0.2 µMol.L-1 of each primer, 200
µMol.L-1 of each deoxynucleotide triphosphate, 1.5 m
Mol.L-1 of MgCl2, 0.3 units of Taq DNA polymerase with
1 × buffer (Qiagen, Chatsworth, CA). The reaction was
conducted under the following conditions: an initial
melting step of 5 min at 95°C; followed by 30 cycles of
30s at 94°C, 30s at 60°C, and 45s at 72°C, respectively;
and a final elongation step of 5 min at 72°C. Automatic
DNA sequencing was performed on an ABI 377 Automatic
Sequencer (Applied Biosystems, Foster City, CA) using the
direct PCR products of the samples according to the man-
ufacture's protocol. The raw data was collected using ABI
PrismTM 377-96 Collection software, and analyzed using
Sequencing Analysis software V3.3 on a MAC operating
system V9.1, Polyphred/Phredphrap/Consed software
package, DNAStar/Taqman software package and CHRO-
MAS. All genotyping was performed blind to case or con-
trol status, and blind quality control samples were used to
validate genotyping. A random sample of 10% of the cases
and controls were sequenced twice by different investiga-
tors to confirm genotyping; our reproducibility was
100%.
Statistical Analysis
For each SNP, deviation from Hardy-Weinberg equilib-
rium (HWE) in the controls was assessed using the stand-
ard  X2  test. For each SNP, the genotypic frequency
differences between cases and controls were tested using
conditional logistic regression. All analyses were per-
formed using Statistical Analysis System software (SAS,
version 8.0, SAS Institute, Cary, NC). The odds ratios
(ORs) and 95 % confidence intervals (CIs) were estimated
using logistic regression. All statistical tests were two-
sided, and a probability level below 0.05(P < 0.05) was
used as the criterion for a significance. Haplotype analyses
were conducted using Haplo.stats, which is a score test
from generalized linear models (GLM) to test associations
between haplotypes and disease under the null hypothe-
sis of no haplotype effect without any assumption about
mode of inheritance. This software provides several differ-
ent global and haplotype-specific tests for association and
allows the possibility to include non-genetic covariates.
Furthermore, it also allows computation of permutation P
values which helps resolve potential problems with sparse
data.
Results
A summary of characteristics of cases and controls is
shown in Table 1. No statistical differences were observed
between cases and controls in the distribution of age (p =
0.6302) and gender (p = 0.6415). Table 1 also describes
the distribution of VCA-IgA antibody titer category of the
cases and controls. The distributions between the two
groups were different (P < 0.05). The level of the VCA-IgA
antibody titer was positively correlated with the occur-
rence of NPC, supporting the hypothesis that EBV is
strongly associated with NPC.
Selecting SNPs
We examined the total length of TLR3, spanning 6.23 kb.
We selected four SNPs, including one SNP (13909C/T,
Table 1: Distribution of characteristics of study subjects
Characteristic Cases (N = 434) Controls (N = 512) p-valuea
Gender, N (%) Male 322(74.19) 373(72.85)
Female 112(25.81) 139(27.15) 0.6415
Age, N(%) < 30 years 102(23.50) 122(23.83)
30–39 years 167(38.48) 186(36.33%)
40–49 years 115(26.50) 131(25.59%)
> = 50 years 50(11.52) 73(14.26%) 0.6302
VCA_IgA(%)b 0 (< 1:10) 28 (6.85) 404(81.65)
1 (1:10–1:20) 32(7.82) 70(14.14)
2 (1:40) 31 (7.58) 16 (3.23) < 0.0001
3 (> = 1:80) 318 (77.75) 5 (1.01 %)
No data 25 17
Note: aP-values obtained from chi-square tests. b Subjects were divided into 4 titer categories: 0, Subjects with VCA-IgA antibody titers less than 1: 
10; 1, Subjects with VCA-IgA antibody titers equal to 1: 10 or 1: 20; 2, Subjects with VCA-IgA antibody titers equal to 1: 40; 3, Subjects with VCA-
IgA antibody titers more than 1:80. Not all the cases and controls have EBV VCA antibody titers available.BMC Cancer 2007, 7:194 http://www.biomedcentral.com/1471-2407/7/194
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rs3775291 in NCBI bank), which causes amino acid sub-
stitutions Leu>Phe, one synonymous (Pro) SNP
(13766C/T, N.D.), two SNPs in the noncoding region
(829A/C in intron1, N.D., and 9948C/T in intron2,
rs5743312). These SNPs with minor allele frequencies
above 5%, were used for additional association studies.
DNA samples extacted from whole blood in 434 sporadic
NPC cases and 512 controls were used for genotyping.
Genotypic distributions in the control subjects did not
differ significantly from HWE (data not shown).
Single SNP association
We analyzed the single SNP association with NPC risk
separately using conditional logistic regression. The esti-
mated odds ratios (ORs) are provided in Table 2. Chi-
squared tests revealed that the variant "829A/C" had a sig-
nificantly different frequency in cases as compared to con-
trols. The frequency of the allele C for the SNP 829A/C
was 14.45% and 10.21% in the cases and controls, respec-
tively (P = 0.0068), and the estimated OR was 1.49
(95%CI: 1.10–2.00). The distributions of the other three
SNPs were not different between cases and controls (Table
2).
Association with haplotypes
We omitted haplotypes with frequencies less than 0.006,
and analyzed the remaining 6 haplotypes with
Haplo.stats to evaluate their effects for each haplotype in
developing NPC. The results are displayed in Table 3.
When adjusted for age, gender and VCA-IgA antibody tit-
ers, the calculated NPC risk was significantly reduced
among individuals who carried the haplotype "ATCT" (p-
value = 0.0054, OR = 0.028, 95% CI (0.002–0.341)),
compared to those who carried the most common haplo-
type "ACCT".
Discussion
Nasopharyngeal carcinoma (NPC) is an endemic multi-
factorial genetic disease, whereas the disease is rare in the
Western world, it occurs with high frequencies in South-
ern China, Southeast Asia, and among the Greenland
Inuit. Genetic susceptibility, EBV infection, environmen-
tal risk factors and certain dietary factors are now thought
to be associated with the etiology of human NPC. EBV
infection has been identified consistently as an important
risk factor for NPC, with a dose-response relationship
between EBV antibodies and NPC risk [43,44]. A high
VCA-IgA antibody titer (> = 1:10) is an index of EBV reac-
tivation. Our results further support the previously
reported literature. The positive rate, detected by VCA-IgA
antibody titer, is 18.35% in control subjects and 93.15%,
respectively in case subjects (Table 1).
TLR3 plays an important role in antiviral responses. In
this study, we hypothesized that genetic variants in TLR3
may be associated with individual susceptibility to NPC.
Therefore, we performed a genetic analysis of TLR3
sequence variants in 434 NPC cases and 512 controls. We
found that the allele C for the SNP 829A/C increased the
overall risk of NPC by 49% in the study population
(95%CI: 1.10–2.00, P = 0.0068). Because cases and con-
trols were matched in age and gender, the difference
between normal control and patients was not likely
caused by these factors. Furthermore, the reasonable sam-
ple size of this study subjects increases our confidence in
interpreting the results.
We also assessed the interaction of these SNPs in NPC
risk. When adjusted for age, gender and VCA-IgA antibody
titers, the risk was significantly lower in individuals who
carried the haplotype "ATCT" (p-value = 0.0054, OR =
0.028; 95% CI (0.002–0.341), compared to those who
Table 2: Allele frequencies of TLR3 SNP and their contributions to the risk for NPC
Variants Cases Controls P-value OR(95% CI)
829A/C
NO. of major allele(%) 681(85.55) 862 (89.79)
NO. of minor allele(%) 115 (14.45) 98 (10.21) 0.0068 1.49(1.10–2.00)
9948C/T
NO. of major allele(%) 640 (79.01) 316 (79.00)
NO. of minor allele(%) 170(20.99) 84 (21.00) 0.9960 1.00(0.74–1.36)
13766C/T
NO. of major allele(%) 565(71.52) 510(68.73)
NO. of minor allele(%) 225 (28.48) 232 (31.27) 0.2338 0.88(0.70–1.10)
13909C/T
NO. of major allele(%) 405 (60.81) 359(62.54)
NO. of minor allele(%) 261 (39.19) 215(37.46) 0.5318 1.08(0.85–1.36)BMC Cancer 2007, 7:194 http://www.biomedcentral.com/1471-2407/7/194
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carried the most common haplotype "ACCT". These
results indicate that the SNPs commonly linked to the
"ATCT" haplotype are likely to be protective. We recog-
nize that the difference in these two haplotypes is caused
by one SNP, 9948C/T.
However, since 9948C/T has no direct association with
NPC and some haplotypes with "9948" for example,
"ACTC" and "ATTC" did not support any direct protective
effect of 9948T, therefore, we conclude that the NPC asso-
ciated SNPs are unknown but linked to the "ATCT" haplo-
type and in strong LD with the SNP 829 A/C. Since the
SNP 829 is located in an intronic region, it by itself should
not possess any direct contribution to the protein func-
tion. Therefore the SNP 829 may only be linked to an
unknown causative SNP.
Although an observed 1.49-fold increase in NPC risk is
modest, this is the magnitude of risk that one would antic-
ipate for a heterogeneous genetic disease. Moreover a sim-
ilar effect on certain genetic variants has been reported for
other diseases that are also related to environmental,
genetic variation and viral infection. For example, the eti-
ology of prostate cancer is associated with genetic altera-
tions in environmental carcinogen metabolism, DNA
repair and virus infection. Each individually related gene
in multiple pathways may alter the risk for prostate can-
cer, and might contribute only modest risk. In addition,
this phenomenon has been observed in other complex
diseases, as reported in a recent meta-analysis on the
genetic association of complex diseases [45]. In this study,
after evaluating 301 published studies that attempted to
replicate reported disease-associations for 25 different
genes, the authors confirmed the disease-associations for
eight of these genes. Interestingly, seven of the eight genes
were associated with modest estimated genetic effects (OR
between 1.07 and 1.76) in the pooled analyses. It was
concluded that there are probably many common variants
in the human genome with modest effects on common
disease risk. Thus, the observed 49% increase in risk in
this study, although modest, are consistent with the
hypothesis of common disease/common variants.
Conclusion
Our study provides evidence of an association between a
TLR3 sequence variant and NPC risk in the Cantonese
population. Although the contribution of the SNPs in
TLR3 is modest, these sequence variations, together with
polymorphisms of other "minor-effect" genes, may define
a genetic susceptibility background for NPC, suggesting
that SNP 829 may linked to the unknown but important
SNPs, and TLR3 gene variation may play an important
role in the occurrence of NPC. If our findings are repli-
cated, it will be valuable to further investigate the patho-
logical role of TLR3 polymorphisms in carcinogenesis.
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Table 3: Haplotype frequencies of the TLR3 and effect of environmental factors revealed by Haplo.GLM




Age 0. 2019 0.975 (0.938–1.01)
VCA_IgAb < 0.0001 9.91 (6.17–15.9)
Haplotypes
Haplo-1 ATCT 0.0070 0.0151 0.0054 0.028 (0.002–0.341)
Haplo-2 ACTC 0.0797 0.1155 0.0587 0.363 (0.127–1.03)
Haplo-3 CCCC 0.1464 0.1132 0.5554 0.752 (0.292–1.94)
Haplo-4 ATTC 0.1753 0.2027 0.7950 1.10(0.528–2.30)
Haplo-5 ACCT 0.3839 0.3576 Not applicable Reference
Haplo-6 ACCC 0.1782 0.1955 0.3789 1.40 (0.663–2.95)
Note: aP-values and ORs for haplotypes were adjusted by sex, age and VCA-IgA. b The P-values and OR for VCA-IgA was based on "per titer 
category" as indicated in Table 1.BMC Cancer 2007, 7:194 http://www.biomedcentral.com/1471-2407/7/194
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